Changeflow GovPing Healthcare & Life Sciences Lysando AG Novel Antimicrobial Fusion Proteins ...
Routine Notice Added Final

Lysando AG Novel Antimicrobial Fusion Proteins EP3802620A1

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The EPO published patent application EP3802620A1 on April 15, 2026, covering novel antimicrobial fusion proteins filed by Lysando AG. Inventors are Manfred Biebl and Martin Griessl, with the invention classified under C07K 19/00, C07K 14/47, and C12N 9/36. The application designates all major EPO member states including DE, FR, GB, IT, NL, ES, BE, CH, and others.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 34 changes logged to date.

What changed

The EPO published patent application EP3802620A1 for Lysando AG covering novel antimicrobial fusion proteins. The publication includes applicant Lysando AG, inventors Manfred Biebl and Martin Griessl, and designated states covering all major EPO member states. This is a patent application publication (Kind A1), indicating the application has been published with the search report. Parties in the antimicrobial therapeutics or biotech space should monitor this application for potential freedom-to-operate implications as the patent prosecution progresses.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NOVEL ANTIMICROBIAL FUSION PROTEINS

Publication EP3802620A1 Kind: A1 Apr 15, 2026

Applicants

Lysando AG

Inventors

BIEBL, Manfred, GRIESSL, Martin

IPC Classifications

C07K 19/00 20060101AFI20191206BHEP C07K 14/47 20060101ALI20191206BHEP C12N 9/36 20060101ALI20191206BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Parties

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3802620A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254.1 Biotechnology
Activity scope
Patent application publication IP registration
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!